Sanner invests in Bensheim production facility
14 new injection-molding machines of the latest generation make Sanner’s production in Bensheim ready for the future.
14 new injection-molding machines and significant increase in efficiency and energy savings.
Sanner has successfully completed the expansion of its production facility in Bensheim. Fourteen new, state-of-the-art injection-molding machines were installed to improve production processes. With an investment of close to 3 million euro, Sanner has paved the way for future-oriented manufacturing at its headquarters.
One year after its start, Sanner has successfully completed the “future project production area South”. During the project, the entire machine park in this area was replaced with 14 injection-molding machines of the latest generation. The Sanner team completed the project on schedule and within the designated budget. “Our goal was to further automatize production and consequently increase capacities and efficiency,” says Dirk Mähr, Managing Director of Sanner GmbH. “A goal we have definitely achieved.”
Ready for industry 4.0
With this expansion, the company is taking another important step towards future-oriented production at its headquarters in Bensheim. The new injection-molding machines ensure faster processes and can be further automatized at any time. The packaging specialist is thus optimally equipped for the challenges of industry 4.0, as well as for further optimization projects. Over the next few years, Sanner will also consequently expand its portfolio in the areas of capsules and desiccant packaging.
Focus on sustainability
“During the modification, we were also able to significantly reduce energy consumption in production in line with the Sanner sustainability concept,” Mähr adds. This includes, amongst others, a renewed media supply for cooling water and compressed air, a better raw material supply and the installation of new cranes. Thanks to new lighting and a reduced noise level, Sanner employees also benefit from easier workflows and better working conditions.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.